Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Botulinum toxin in multiple sclerosis.

Wolfgang H Jost1

  • 1Dept. of Neurology, Deutsche Klinik für Diagnostik, Aukammallee 33, 65191, Wiesbaden, Germany. jost.neuro@dkd-wiesbaden.de

Journal of Neurology
|February 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same author

The German Parkinson expert meetings.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Editorial: Cognition in Parkinson's disease.

Frontiers in cognition·2026
Same author

Beyond "Advanced": proposing Fluctuation-Dominant Parkinson's disease as a functional alternative to enable timely device-aided therapy.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.

Neurology and therapy·2026
Same author

Are We Heading into a Dead End, or Are We Treading Water?

Toxins·2026
Same journal

The dual role of mTOR in multiple sclerosis pathophysiology: a systematic review.

Journal of neurology·2026
Same journal

Brain-first versus body-first Parkinson's disease: Differential findings on pupillary, brainstem and vagus sonography.

Journal of neurology·2026
Same journal

Spontaneous intracranial hypotension due to pelvic cerebrospinal fluid leak.

Journal of neurology·2026
Same journal

Morbidity and medication use preceding a diagnosis of late-onset Alzheimer's disease: a Danish nationwide study.

Journal of neurology·2026
Same journal

Comorbid autoimmune disease in stiff-person syndrome spectrum disorder: a systematic review and meta-analysis.

Journal of neurology·2026
Same journal

Tetrahydrocannabinol/cannabidiol in the treatment of restless legs syndrome.

Journal of neurology·2026
See all related articles

Local botulinum toxin (BoTx) injections effectively treat focal spasticity and show promise for bladder disorders and other conditions. However, restricted approval limits its widespread therapeutic use.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Botulinum toxin (BoTx) inhibits acetylcholine release, causing paralysis of innervated muscles and glands.
  • Previous studies indicate positive outcomes for focal spasticity in multiple sclerosis patients.

Purpose of the Study:

  • To explore the therapeutic applications of botulinum toxin (BoTx) beyond focal spasticity.
  • To evaluate the efficacy of BoTx in treating neurological conditions including bladder disorders and hyperhidrosis.

Main Methods:

  • Review of existing studies on botulinum toxin (BoTx) applications.
  • Analysis of clinical data regarding BoTx efficacy in multiple sclerosis, bladder disorders, and other conditions.

Main Results:

  • Botulinum toxin (BoTx) demonstrated effectiveness in managing focal spasticity, particularly in extremities.

Related Experiment Videos

  • Promising results were observed in treating bladder disorders like detrusor sphincter dyssynergia and detrusor hyperreflexia.
  • Potential applications include hyperhidrosis, hypersalivation, and proctologic symptoms.

    • Conclusions:

    • Botulinum toxin (BoTx) offers therapeutic benefits for various conditions, including spasticity and bladder dysfunction.
    • Despite promising results, restricted regulatory approval significantly hampers the broader clinical utilization of botulinum toxin (BoTx).